U.S. Court Action Could Jeopardize Ranbaxy-Daiichi Merger Plans
This article was originally published in PharmAsia News
Executive Summary
U.S. allegations Ranbaxy Laboratories may have adulterated some generic drugs marketed in the United States could trouble the proposed purchase of India's largest drug maker by Japan's Daiichi Sankyo. Drug industry analysts are concerned the nature of the accusations leveled in a motion in U.S. court by the Justice Department could derail the merger plan. Experts believe Ranbaxy already must have informed Daiichi about the investigation, which the Indian company has acknowledged publicly is taking place. A Daiichi spokesperson said the firm was studying legal liabilities involved. (Click here for more
You may also be interested in...
Ranbaxy Denies Fraudulent Conduct Alleged By U.S. FDA As Rumors Swirl About Daiichi Deal
Ranbaxy has denied U.S. FDA allegations that it conducted "systematic fraudulent conduct" related to concealing violations of current good manufacturing practices
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.